GHRP-2 potential benefits and areas of research

GHRP-2's demonstrated benefits are narrower and better documented than the marketing suggests. It reliably and repeatably releases growth hormone in humans — reliably enough that Japanese endocrinology uses it as a stimulation test in place of the insulin tolerance test. Sustained dosing raises IGF-1 and keeps it raised for at least a month. And it makes people hungry: healthy men given a subcutaneous infusion ate 35.9% more at a buffet meal than on saline (Laferrère et al., J Clin Endocrinol Metab 2005). What no study has measured is whether any of that translates into muscle, fat loss, or recovery.

Diagnosing growth hormone deficiency traditionally requires an insulin tolerance test — deliberately inducing hypoglycaemia, which is unpleasant and contraindicated in people with seizure disorders or cardiac disease. GHRP-2 provides an alternative stimulus, and in Japan it is the recommended one: the GHRP-2 test is described as a convenient and safe GH-stimulating test, with a peak GH concentration below 9 µg/L defining severe adult GH deficiency (Fukuda et al., Neurol Med Chir 2014).

It performs in children too. In 56 children with growth disorders, a 2 µg/kg intravenous dose produced peak GH values correlating strongly with the insulin tolerance test (p < 0.0001); median peak was 3.39 µg/L in children with GH deficiency versus 25.10 µg/L in those without, and the test took an hour or less (Asakura et al., J Pediatr Endocrinol Metab 2010).

This matters for reading everything else on the page. GHRP-2's evidence base is a diagnostic evidence base — it establishes that the compound provokes a measurable, interpretable GH pulse. It says nothing about what repeated provocation does over months.

The most informative therapeutic-direction study remains a 2004 investigation in healthy older men and women. Continuous subcutaneous delivery of GHRP-2 at 1 µg/kg/h for 30 days, in 17 subjects:

• Stimulated pulsatile GH secretion more than three-fold on day 1, and more than 1.8-fold on days 14 and 30 (each p < 0.001 versus saline).
• Raised IGF-1 to a stable plateau present on days 1, 14 and 30 (p < 0.025 versus baseline).
• Increased IGF-binding protein-3 and IGFBP-5 by day 14 and/or 30.
• Left safety screening tests normal throughout.

(Bowers et al., J Clin Endocrinol Metab 2004.)

Read the first bullet carefully: the GH response at 30 days was roughly half what it was on day 1. The axis stayed activated — IGF-1 held its plateau — but the acute pulse attenuated. That is the partial desensitisation described across this drug class, and it is the pharmacological basis for the "cycle off" convention, visible here in numbers rather than anecdote.

The same study also quantified something relevant to how these peptides are stacked: co-infusion of GHRP-2 with GHRH for 24 hours drove more GH secretion than either agonist alone, and the acute two-peptide synergy was about three-fold greater in young than older volunteers and 2.3-fold higher in elderly women than men.

GHRP-2 is a ghrelin mimetic, and ghrelin is the body's hunger signal, so appetite stimulation is a mechanism-level prediction. It has been tested. Seven lean healthy men received either GHRP-2 at 1 µg/kg/h or saline by subcutaneous infusion for 270 minutes, then ate from an ad libitum buffet. On GHRP-2 they consumed 35.9 ± 10.9% more — 32.5 kcal/kg versus 24.2 kcal/kg on saline (p = 0.008) — with no change in the macronutrient mix they chose (Laferrère 2005).

Whether that is a benefit depends entirely on the goal. In wasting states or poor appetite it is the point. For someone using GHRP-2 while trying to lose fat, it is the single most predictable effect of the compound working directly against the reason they are taking it.

No published trial of GHRP-2 has used lean mass, fat mass, strength, sleep quality, injury recovery, or physical function as an endpoint. The closest proxy in the class is the two-year MK-677 trial in 65 healthy older adults, where GH and IGF-1 rose into the young-adult range and fat-free mass increased by about 1.1 kg — but strength and function did not improve, and fasting glucose rose while insulin sensitivity fell (Nass et al., Ann Intern Med 2008). That is the best-documented template for what a working secretagogue delivers: hormone endpoints succeed; functional endpoints do not automatically follow.

GHRP-2 is also prohibited in sport at all times under WADA section S2; anti-doping laboratories detect it and its metabolites in urine for up to 47 hours after administration (Semenistaya et al., Drug Test Anal 2015).

See also GHRP-2 side effects and dosing education.